156. レット症候群 Rett syndrome Clinical trials / Disease details


臨床試験数 : 44 薬物数 : 61 - (DrugBank : 23) / 標的遺伝子数 : 57 - 標的パスウェイ数 : 83

  
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2015-004448-20-GB
(EUCTR)
28/11/201623/09/2016Sarizotan: Treatment in patients with Rett Syndrome with Respiratory Symptoms.A Randomized, Double-Blind, Placebo-Controlled, Six-Month Study to Evaluate the Efficacy, Safety and Tolerability of Sarizotan in Patients with Rett Syndrome with Respiratory Symptoms Rett syndrome
MedDRA version: 20.0;Level: LLT;Classification code 10039000;Term: Rett's disorder;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Name: sarizotan hydrochloride
Product Code: EMD 128130
INN or Proposed INN: sarizotan hydrochloride
Other descriptive name: SARIZOTAN HYDROCHLORIDE
Product Name: sarizotan hydrochloride
Product Code: EMD 128130
INN or Proposed INN: sarizotan hydrochloride
Other descriptive name: SARIZOTAN HYDROCHLORIDE
Product Name: sarizotan hydrochloride
Product Code: EMD 128130
INN or Proposed INN: sarizotan hydrochloride
Other descriptive name: SARIZOTAN HYDROCHLORIDE
Newron Pharmaceuticals S.p.A.NULLNot RecruitingFemale: yes
Male: yes
129Phase 2United States;Australia;Italy;United Kingdom;India
2NCT02790034
(ClinicalTrials.gov)
August 201624/5/2016Evaluation of the Efficacy, Safety, and Tolerability of Sarizotan in Rett Syndrome With Respiratory SymptomsA Randomised, Double-Blind, Placebo-Controlled 6-month Study to Evaluate the Efficacy, Safety, and Tolerability of Sarizotan in Patients With Rett Syndrome With Respiratory SymptomsRett SyndromeDrug: Sarizotan;Drug: PlaceboNewron Pharmaceuticals SPANULLTerminated4 YearsN/AAll129Phase 2/Phase 3United States;Australia;India;Italy;United Kingdom